There are two drugs now approved for RET-positive NSCLC and both are kinase inhibitors: Pralsetinib (Gavreto) Selpercatinib (Retevmo). They work to block the enzyme and inhibit tumor growth.

Retevmo (selpercatinib) is a medicine that is used in adults for certain types of non-small-cell lung cancer (NSCLC) that have a certain fusion in a gene known as receptor tyrosine kinase (RET).

was approved in 2020 by the FDA to treat adults with metastatic RET fusion-positive non-small-cell lung cancer (NSCLC), shortly after Roche paid $775 million upfront to license the drug.

Gavreto (pralsetinib) has been cleared as a first-line treatment of people with RET fusion-positive advanced non-small cell lung cancer (NSCLC), a disease that is diagnosed in around 37,000 people ...

However, when aberrantly activated due to mutations or chromosomal rearrangements, RET can act as an oncogenic driver in many cancers, notably non-small cell lung cancer (NSCLC). The review ...

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK) announced that it will present results from six Kelun-led clinical studies at the 2025 American Society of Clinical Oncology (ASCO) Annual ...

have approved sugemalimab in combination with platinum-based chemotherapy for the first-line treatment of patients with metastatic NSCLC with no sensitizing EGFR mutations, or ALK, ROS1 or RET ...